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Antibiotics for cancer therapy 
Richard G. Pestell and Albert A. Rizvanov
Elegant studies by Lisanti, Sotgia and co-workers 
demonstrate that when breast cancer cells are grown under 
conditions that promote 3D-sphere formation, which 
selects for cancer stem cells, that mitochondrial proteins 
are dramatically induced. Importantly, these studies also 
show that antibiotic agents that function as mammalian 
inhibitors of mitochondrial biogenesis, are selectively 
toxic to cancer stem cells, when grown as mammospheres 
[1, 2]. The effects of antibiotics on mitochondrial 
biogenesis can be explained by the ‘endosymbiotic 
theory of mitochondrial evolution’, according to which 
mitochondria directly evolved from bacteria. This is why 
drugs that target prokaryotic protein synthesis interfere 
with eukaryotic mitochondrial biogenesis. 
The role of mitochondrial metabolism in stem cells 
and cancer is complex. Stem cells and cancer stem cells 
have distinct characteristics and the techniques used to 
analyze these types of cells have often given different 
results. For example, there is an apparent disparity 
between transplantation and lineage tracing experiments 
analyzing mammary gland stem cells.
The metabolism of stem cells differs from normal 
cells. Undifferentiated embryonic stem cells as well as 
adult stem cells differ from fully differentiated cells. 
Stem cells rely mostly on anaerobic metabolism, rather 
than oxidative phosphorylation. In undifferentiated stems 
cells, the number of mitochondria are reduced with 
a low content of mtDNA and a reduced rate of oxygen 
consumption, as well as a low level of intracellular 
ATP and reactive oxygen species, consistent with a 
quiescent state. However, intact mitochondrial function is 
crucial for the maintenance of stem cells, as evidenced 
by compromised hematopoietic stem cell function, 
profound anemia and lymphopenia in mice expressing a 
mutant form of mitochondrial DNA polymerase-γ that is 
associated with increased mitochondrial DNA mutations.
In contrast with the reduction in mitochondrial mass 
in normal stem cells, Lisanti and colleagues demonstrated 
an increase in mitochondrial protein abundance in breast 
cancer stem cells, defined by growth as mammospheres. 
In studies conducted in the early 1980s, tumor carcinoma 
cells, induced by chemical carcinogens or v-fos correlated 
with an increase in mitochondrial membrane potential. 
This increase in mitochondrial membrane potential upon 
oncogenic transformation was the basis of screening 
for mitochondrio-toxic drugs that selectively inhibit 
tumor growth [3]. Oncogenes and tumor suppressors 
govern mitochondrial biogenesis as either cyclin D1 
overexpression, or pRB deletion have similar affects 
to inhibit mitochondrial biogenesis, via inactivation of 
NRF1, and thereby MtTFA, to thereby enhance cytosolic 
glycolysis [4, 5], as observed in the Warburg effect.
In the studies by Sotgia, Lisanti and co-workers, 
the proteomic analysis conducted on mammary stem 
cells, identified an increased abundance of mitochondrial 
proteins in two distinct breast cancer cell lines. The notion 
that such a change may confer increased sensitivity to 
antibiotics was examined by treating 3D tumor-spheres 
and indeed the number of colonies was reduced in 12 
cell lines representing 8 different types of cancer, without 
affecting normal fibroblasts or cells in monolayer. 
Importantly this is in contrast to the effect of antibiotics, 
which enhance the renewal of non-malignant stem cells 
[6]. Further pre-clinical in vivo studies are warranted as 
the local tissue microenvironment creates a metabolic 
asymmetry and distinct cell types may have different 
response to these agents. The bioequivalent dose required 
to block cancer stem cells should be assessed carefully, 
and the mechanism examined further, given that prior 
studies suggest that antibiotics can also affect kinase 
signaling pathways and the secretion of cytokines, 
including IL-8 [7], which is known to promote cancer 
stems cell expansion. 
The evidence that antibiotics may reduce the 
viability and clonal expansion of cancer stem cells is of 
broad importance, as cancer stem cells are increasingly 
accepted as a distinct cell type that gives rise to therapy 
resistance, tumor recurrence and distant metastasis.
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